Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Erlangen
Clinical trial register · Germany

Clinical Trials in Erlangen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5082 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:18 UTC
5082
Studies in scope
all four open statuses
2886
Recruiting now
open to new participants
989
Lead sponsors
across recruiting studies
Top sites
Berlin 9 Multiple Locations 8 Heidelberg 6 Bonn 5 Cologne 5
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Erlangen-Nürnberg Medical School45 AstraZeneca27 AbbVie17 Merck Sharp & Dohme LLC13 Hoffmann-La Roche12 Janssen Research & Development, LLC12 Novartis Pharmaceuticals11 Eli Lilly and Company10 Bristol-Myers Squibb10 Boehringer Ingelheim7 Incyte Corporation6 Institut fuer Frauengesundheit5 German Cancer Research Center5 Miltenyi Biomedicine GmbH5 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company5 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest4 Friedrich-Alexander-Universität Erlangen-Nürnberg4 Medtronic Vascular3 Pfizer3 GlaxoSmithKline3 Edwards Lifesciences3 Gilead Sciences3 Universität des Saarlandes3 UCB Biopharma SRL3 Biohaven Therapeutics Ltd.2 Wuerzburg University Hospital2 Chugai Pharmaceutical2 Goethe University2 Galderma R&D2 Cullinan Therapeutics Inc.2 Alexion Pharmaceuticals, Inc.2 Weill Medical College of Cornell University2 Stemline Therapeutics, Inc.2 Sanofi2 Jena University Hospital2 Biogen2 ReCor Medical, Inc.2 LEO Pharma2 Universitätsklinikum Hamburg-Eppendorf2 University Hospital Erlangen2 Immatics Biotechnologies GmbH2 Immunocore Ltd2 Technische Universität Dresden2 MoonLake Immunotherapeutics AG2 Celldex Therapeutics2 Heidelberg University2 Bayer2 Abivax S.A.2 ITM Solucin GmbH2 University of Ulm1 Regeneron Pharmaceuticals1 Children's Oncology Group1 VectivBio AG1 Helios Health Institute GmbH1 University Medical Center Groningen1 University of Jena1 Pharmazz, Inc.1 Day One Biopharmaceuticals, Inc.1 University Hospital, Basel, Switzerland1 Philips Clinical & Medical Affairs Global1 A.M.I. Agency for Medical Innovations GmbH1 Abiomed Inc.1 Vertex Pharmaceuticals Incorporated1 Lohmann & Rauscher1 Astellas Pharma Global Development, Inc.1 Institut für Pharmakologie und Präventive Medizin1 Almirall, S.A.1 Joseph Broderick, MD1 Occlutech International AB1 Charite University, Berlin, Germany1 Swedish Orphan Biovitrum1 MediWound Ltd1 Alliance Foundation Trials, LLC.1 CytoSorbents, Inc1 Dr. med. Sonja Diez1 BioNTech SE1 University Hospital Augsburg1 National Institute of Oncology, Hungary1 Quell Therapeutics Limited1 Prilenia1 Advanced Accelerator Applications1 University College, London1 Celgene1 Smith & Nephew, Inc.1 DBV Technologies1 Dr. Andreas Ziegler1 Heinrich-Heine University, Duesseldorf1 Biotronik SE & Co. KG1 Nektar Therapeutics1 Andreas Stallmach1 H. Lundbeck A/S1 OWKIN1 Abbott Medical Devices1 Dr. Rebecca Schule1 SoniVie Inc.1 Prof. Dr. Paul Brinkkoetter1 Relay Therapeutics, Inc.1 Princess Maxima Center for Pediatric Oncology1 DualityBio Inc.1 Wolfgang Kemmler, PhD1 AO Foundation, AO Spine1 Insel Gruppe AG, University Hospital Bern1 Dompé Farmaceutici S.p.A1 University Eye Hospital, Freiburg1 Ipsen1 Amgen1 SK Life Science, Inc.1 Camurus AB1 AvenCell Therapeutics, Inc.1 Elixir Medical Corporation1 Mirum Pharmaceuticals, Inc.1 University Hospital Tuebingen1 CHDI Foundation, Inc.1 AnaptysBio, Inc.1 John Neoptolemos1 Alumis Inc1 Universität Münster1 TORL Biotherapeutics, LLC1 Hannover Medical School1 Ludwig-Maximilians - University of Munich1 Immunovant Sciences GmbH1 Eikon Therapeutics1 Columbia University1 Exactech1 Microvention-Terumo, Inc.1 University of Oxford1 University Hospital Freiburg1 European Organisation for Research and Treatment of Cancer - EORTC1 RWTH Aachen University1 Exelixis1 IO Biotech1 Medtronic Neurovascular Clinical Affairs1 EspeRare Foundation1 Immatics US, Inc.1 Genentech, Inc.1 IDEAYA Biosciences1 Blueprint Medicines Corporation1 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz1 University Hospital Muenster1 Genmab1 St. Anna Kinderkrebsforschung1 Novo Nordisk A/S1 University of Regensburg1 Esteve Pharmaceuticals, S.A.1 Grey Wolf Therapeutics1 Kite, A Gilead Company1 EBR Systems, Inc.1 Philipps University Marburg1 University of Leipzig1 NEC Bio B.V1 Pierre Fabre Pharma GmbH1 BioNTech Cell & Gene Therapies GmbH1 enGene, Inc.1 Clear sponsor filter
Target enrolment
to

Trials with a site in Erlangen

2 of 5082 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Active, closed
Bayer
Phase 3
774
Emmendingen, Freiburg im Breisgau, Mühlacker, Nürtingen, Reutlingen, Tübingen, Erlangen, Braunschweig
2020-10-20
Rows per page Showing 1–2 of 2
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-germany/city/erlangen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,082 studies in total at the last sync on 17 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2 of those studies with a site in Erlangen that also match the filters currently applied.

How many clinical trials are recruiting in Erlangen?

0 of the 2 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Erlangen), 2 studies
PhaseStudiesRecruitingShare
Phase 21050%
Phase 31050%

Most active sponsors

Lead sponsors with the most studies (Erlangen)
Lead sponsorStudiesRecruiting
Bayer20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.